Evidence map›Paper›PMID 40093741›Full record

ArticleClinical and translational radiation oncology2025

Recovery of quality of life in 574 patients with inoperable lung cancer undergoing (chemo)radiotherapy.

Marloes Nies, Robin Wijsman, Olga Chouvalova, Fred J F Ubbels, Harriët J Elzinga, Ellen Haan-Stijntjes, Marleen Woltman-van Iersel, Pieter R A J Deseyne, Stefanie A de Boer, Johannes A Langendijk and 2 more

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marloes NiesDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Robin WijsmanDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Olga ChouvalovaDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Fred J F UbbelsDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Harriët J ElzingaDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Ellen Haan-StijntjesDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Marleen Woltman-van IerselDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Pieter R A J DeseyneDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Stefanie A de BoerDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Johannes A LangendijkDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Joachim WidderDepartment of Radiation Oncology, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria.
Anne G H NiezinkDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Quality of life (QoL) of patients with inoperable lung cancer can be negatively affected by both the disease and its treatment, generally consisting of (chemo)radiotherapy. The aim of this study was to prospectively assess QoL in patients with inoperable lung cancer, treated with (chemo)radiotherapy and to assess whether patient- and/or treatment-related characteristics were associated with poorer QoL. Methods: This prospective cohort study evaluated QoL and patient-, tumor-, and treatment characteristics from inoperable lung cancer patients, treated with fractionated (≥40 Gy) (chemo)radiotherapy. Patients were evaluated at baseline, upon finishing radiotherapy, and 3 months, 6 months, 1 year, and yearly thereafter up to 5 years after radiotherapy. The QoL assessment consisted of questionnaires evaluating lung cancer-specific and treatment-related complaints using scale scores. Results: Compliance rates of the 574 analyzed patients ranged from 87 to 97 % during follow-up. Complaints increased after radiotherapy, as the QoL scale scores increased from median 8 (interquartile range, IQR 4-14) to 17 (IQR 4-25) after completing radiotherapy (P < 0.0004), indicating more complaints. From 3 months to 24 months of follow-up, scale scores returned to a median of 13, but were significantly higher compared to baseline (P < 0.0004). However, no clinically relevant differences compared to baseline were observed. Patients with pulmonary comorbidity and WHO scores ≥ 2 generally reported more complaints. Conclusion: Patients experienced a temporary increase in complaints after finishing (chemo)radiotherapy, QoL returned to baseline level and remained stable up to five years of follow-up.

Indexed as

ChemotherapyLung cancerQuality of lifeRadiotherapy

Identifiers

PMID40093741
PMCPMC11908382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.